LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "novartis pharmaceuticals" as a keyword



Photo from wikipedia

AB0931 Persistence with subcutaneously administered biologics among patients with psoriatic arthritis: analyses from a us claims database

Sign Up to like & get
recommendations! Published in 2018 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2018-eular.1593

Abstract: Background Persistence with biologic therapies among patients with psoriatic arthritis (PsA) provides insight into the real-world effectiveness of biologics in routine clinical practice. With different dosing schedules and durations of action of currently available biologics,… read more here.

Keywords: treatment gap; gap; index; treatment ... See more keywords
Photo from wikipedia

THU0560 PRIMARY CARE PHYSICIAN PERSPECTIVES ON DELAYS IN DIAGNOSIS OF AXIAL SPONDYLOARTHRITIS: A QUALITATIVE STUDY

Sign Up to like & get
recommendations! Published in 2020 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2020-eular.2004

Abstract: Background: The average delay in diagnosis for patients with any form of spondyloarthritis (SpA) ranges from 7 to 10 years [1–5]. In axial spondyloarthritis (axSpA), a subgroup of SpA, it is 5 to 14 years… read more here.

Keywords: care; primary care; novartis pharmaceuticals; novartis ... See more keywords
Photo from wikipedia

Patient Profile and Treatment Patterns in a Commercially Insured Population with Follicular Lymphoma

Sign Up to like & get
recommendations! Published in 2019 at "Blood"

DOI: 10.1182/blood-2019-127237

Abstract: Introduction: Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma in the Western hemisphere. Patient characteristics and burden of FL are incomplete and vary from previous studies. This study evaluated patient profile, including patient… read more here.

Keywords: line; first line; treatment; novartis pharmaceuticals ... See more keywords
Photo by mbaumi from unsplash

Impact of Humoral Immunogenicity (Anti-mCAR19 Antibodies) on CTL019 Cellular Kinetics, Efficacy, and Safety

Sign Up to like & get
recommendations! Published in 2017 at "Blood"

DOI: 10.1182/blood.v130.suppl_1.1281.1281

Abstract: Background: The humoral immunogenicity of CAR19, a chimeric antigen receptor with a murine scFV domain developed for treatment with CTL019 (tisagenlecleucel) in relapsed/refractory (R/R) pediatric and young adult acute lymphoblastic leukemia (ALL), was evaluated in… read more here.

Keywords: anti mcar19; pharmaceuticals corporation; mcar19 antibodies; novartis pharmaceuticals ... See more keywords
Photo by officestock from unsplash

The Economic Value of CTL019 Therapy for Pediatric Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia in the United Kingdom

Sign Up to like & get
recommendations! Published in 2017 at "Blood"

DOI: 10.1182/blood.v130.suppl_1.1330.1330

Abstract: Introduction : Pediatric B-cell acute lymphoblastic leukemia (pALL) affects approximately 400 new patients in the United Kingdom (UK) each year (Pediatric Blood & Cancer 2017;00:e26615). With current therapies, approximately 80% of patients achieve remission; however… read more here.

Keywords: value; ctl019; consumer; novartis pharmaceuticals ... See more keywords